Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin

NCT03464968 is registered in ClinicalTrials.gov with Seoul National University Bundang Hospital as lead sponsor.

NCT NCT03464968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03464968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin
Lead sponsor
Seoul National University Bundang Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 29, 2015
Completion date
July 25, 2020
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary cancer metastatic